I think its a fair and reasonable question. I have been in the stock about 8-9 months now. Initially, when the PPS went up their was some trade groups who took a rather large position while the company was starting to make their intentions public regarding its business plan and potential for commercial success (within their portfolio). Unfortunately, they made their trading profit and quickly left...this stock was being pumped up beyond belief.
However, the cash situation has been rather bleak up to relationship established with Dominion capital. There was too much risk and uncertainty as to LymPro's future success, did MANF work and how the bills were to get paid.
In the last 6 months, we have make substantial progress with obtaining funding (from Dominion), adding new strategic advisors, updating the investment community on the continued progress with LymPro, announced Orphan data for MANF, and many science abstracts have been posted and published reinforcing the likelihood that MANF has enormous potential.
In summary, this company has incredible potential on both the Drug development and Diagnostic side...and as the cash situation and balance sheet have been cleaned up...the PPS is starting to rise one again. GLTA!!!
Market Data 
Markets 
